Cited by 28Ocular Disorders and TreatmentsRetinal Development and DisordersGenetic and rare skin diseases.

Gene dosage manipulation alleviates manifestations of hereditary PAX6 haploinsufficiency in mice

Open access
Rabiee, Behnam, Anwar, Khandaker N., Shen, Xiang, Putra, Ilham, Liu, Mingna, Jung, Rebecca, Afsharkhamseh, Neda, Rosenblatt, Mark I. +4 more·2020·Science Translational Medicine

Abstract

Pharmacological induction of wild-type PAX6 allele improved ocular abnormalities induced by PAX6 haploinsufficiency in mice.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aaz4894

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In vivo partial rescue of the aniridia phenotype was obtained in an AAK mouse model by either topical or oral administration of the MEK inhibitor PD0325901, which restored normal Pax6 protein levels.

    “An in vivo partial rescue of the aniridia phenotype was obtained in an AAK mouse model by either a topical or oral administration treatment with the MEK inhibitor PD0325901, which restored normal Pax6 protein levels [ 172 ]”

    From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [172]

    The Methods identify PD0325901 as the drug given orally or topically, and the Results report improved corneal features with both routes in Pax6Sey-Neu/+ mice. The Results show PAX6 protein expression approaching wild-type levels after topical treatment (92 ± 12% versus 100% in wild type), but do not establish that oral treatment also restored PAX6 protein levels. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [9]Traboulsi EI, in Ocular Disease (Elsevier, 2010), pp. 472– 477.

Cited by

Sorted by citations

Authors
Rabiee, B., Anwar, K. N., Shen, X., Putra, I., Liu, M., Jung, R., Afsharkhamseh, N., Rosenblatt, M. I., Fishman, G. A., Liu, X., Ghassemi, M., & Djalilian, A. R.
Affiliations
  • University of Illinois Chicago (US)
  • University of Virginia (US)
Corresponding author
Djalilian, Ali R.
Venue
Science Translational Medicine
Published
2020-12-09
Volume
12
Issue
573
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W3111351675
Cited by
28
References
69
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 7 · 2021: 7
FWCI
2.93
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (R01EY026286, R01EY029121)
  • National Eye Institute (R01-EY024349, EY01792)
  • Research to Prevent Blindness (Unrestricted Grant, Physician-Scientist Award)
  • Eversight
  • Vision for Tomorrow
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Ocular Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and rare skin diseases.
Keywords
Pax6, haploinsufficiency, MEK inhibitors, PD0325901, drug repurposing, corneal opacity, corneal morphology, ocular function, corneal epithelium, mouse model
MeSH terms
PAX6 Transcription Factor, Animals, Eye Proteins, Repressor Proteins, Homeodomain Proteins, Gene Dosage, Mice, Paired Box Transcription Factors, Haploinsufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review